<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318135</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322/OCT-005</org_study_id>
    <secondary_id>JapicCTI-090902</secondary_id>
    <secondary_id>U1111-1119-6196</secondary_id>
    <nct_id>NCT01318135</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan</brief_title>
  <official_title>A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea
      (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both insulin hyposecretion and insulin-resistance are considered to be involved in the
      development of type 2 diabetes mellitus.

      Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients
      with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV
      (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2
      peptide hormones released in response to nutrient ingestion. It is expected that inhibition
      of DPP-IV will improve glycemic control in patients with type 2 diabetes.

      This was a phase 2/3, multicenter, open-label study, in participants who had completed the
      core phase 2/3 sulfonylurea add-on study (SYR-322/CCT-005; NCT01318083) or the core phase 2/3
      metformin add-on study (SYR-322/CCT-006; NCT01318109) to evaluate the safety and efficacy of
      alogliptin administered as an add-on to a sulfonylurea (glimepiride) or metformin
      continuously for 40 weeks (52 weeks from the start of study treatment with alogliptin in the
      core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events.</measure>
    <time_frame>52 Weeks.</time_frame>
    <description>Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 8).</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 12).</measure>
    <time_frame>Baseline and Week 12.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 16).</measure>
    <time_frame>Baseline and Week 16.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 20).</measure>
    <time_frame>Baseline and Week 20.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 24).</measure>
    <time_frame>Baseline and Week 24.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 28).</measure>
    <time_frame>Baseline and Week 28.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 32).</measure>
    <time_frame>Baseline and Week 32.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 36).</measure>
    <time_frame>Baseline and Week 36.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 40).</measure>
    <time_frame>Baseline and Week 40.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 44).</measure>
    <time_frame>Baseline and Week 44.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 48).</measure>
    <time_frame>Baseline and Week 48.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Week 52).</measure>
    <time_frame>Baseline and Week 52.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (Final Visit).</measure>
    <time_frame>Baseline and Final Visit (up to 52).</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 8).</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 8 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 12).</measure>
    <time_frame>Baseline and Week 12.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 12 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 16).</measure>
    <time_frame>Baseline and Week 16.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 6 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 20).</measure>
    <time_frame>Baseline and Week 20.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 20 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 24).</measure>
    <time_frame>Baseline and Week 24.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 24 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 28).</measure>
    <time_frame>Baseline and Week 28.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 28 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 32).</measure>
    <time_frame>Baseline and Week 32.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 32 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 36).</measure>
    <time_frame>Baseline and Week 36.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 36 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 40).</measure>
    <time_frame>Baseline and Week 40.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 40 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 44).</measure>
    <time_frame>Baseline and Week 44.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 44 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 48).</measure>
    <time_frame>Baseline and Week 48.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 48 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Week 52).</measure>
    <time_frame>Baseline and Week 52.</time_frame>
    <description>The change between the value of fasting blood glucose collected at week 52 and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (Final Visit).</measure>
    <time_frame>Baseline and Final Visit (up to Week 52).</time_frame>
    <description>The change between the value of fasting blood glucose collected at final visit and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).</measure>
    <time_frame>Baseline and Week 12.</time_frame>
    <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).</measure>
    <time_frame>Baseline and Week 24.</time_frame>
    <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).</measure>
    <time_frame>Baseline and Week 52.</time_frame>
    <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).</measure>
    <time_frame>Baseline and Final Visit (up to Week 52).</time_frame>
    <description>The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and glimepiride</intervention_name>
    <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
    <arm_group_label>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</arm_group_label>
    <other_name>SYR-322</other_name>
    <other_name>Amaryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and glimepiride</intervention_name>
    <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
    <arm_group_label>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</arm_group_label>
    <other_name>SYR-322</other_name>
    <other_name>Amaryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and metformin</intervention_name>
    <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
    <arm_group_label>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</arm_group_label>
    <other_name>SYR-322</other_name>
    <other_name>Glycoran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and metformin</intervention_name>
    <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
    <arm_group_label>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</arm_group_label>
    <other_name>SYR-322</other_name>
    <other_name>Glycoran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Common criteria that applied to participants completing both the core phase 2/3
        sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:

          1. Had completed the core phase 2/3 sulfonylurea add-on study or the core phase 2/3
             metformin add-on study.

          2. Was capable of understanding and complying with protocol requirements.

          3. Signed a written informed consent form prior to the initiation of any study procedure.

        Exclusion Criteria:

        Common criteria that applied to participants completing both the core phase 2/3
        sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:

          1. With clinical manifestation of hepatic impairment (eg, an aspartate aminotransferase
             or alanine aminotransferase value of 2.5 times or more of the upper reference limit at
             Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin
             add-on study).

          2. With clinical manifestation of renal impairment (eg, a creatinine value of 1.5 times
             or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea
             add-on study or the core phase 2/3 metformin add-on study).

          3. With serious cardiac disease, cerebrovascular disorder, or serious pancreatic or
             hematological disease (eg, a subject who requires hospital admission).

        Criteria that applied only to participants completing the core phase 2/3 metformin add-on
        study:

        1. With history or symptoms of lactic acidosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor, Diabetes and Endocrine Division</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medicine, Kawasaki Medical School</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <results_first_submitted>June 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2012</results_first_posted>
  <last_update_submitted>July 7, 2012</last_update_submitted>
  <last_update_submitted_qc>July 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus - Type 2</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled at 58 investigative sites in Japan from 06 January 2009 to 23 January 2010.</recruitment_details>
      <pre_assignment_details>Participants who had completed a core phase 2/3 glimepiride (SYR-322/CCT-005; NCT01318083) or metformin (SYR-322/CCT-006; NCT01318109) add-on study were enrolled in one of four, once daily (QD) or twice-daily (BID) treatment groups. Five participants completed OCT-005 study without receiving the study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CCT/005 - 12.5 mg Dose Group* → 12.5 mg Combination Group</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
*for participants from the 12.5 mg combination dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study.</description>
        </group>
        <group group_id="P2">
          <title>CCT/005 - 25 mg Dose Group* → 25 mg Combination Dose Group</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
*for participants from the 25 mg combination dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study.</description>
        </group>
        <group group_id="P3">
          <title>Glimepiride Monotherapy Group* → 12.5 mg Combination Group</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
*for participants from the glimepiride 1, 2, 3 or 4 mg dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study.</description>
        </group>
        <group group_id="P4">
          <title>Glimepiride Monotherapy Group* → 25 mg Combination Group</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
*for participants from the glimepiride 1, 2, 3 or 4 mg dosing ARM of the SYR-322/CCT-005 (NCT01318083) core phase 2/3 glimepiride add-on study.</description>
        </group>
        <group group_id="P5">
          <title>CCT/006 - 12.5 mg Dose Group* → 12.5 mg Combination Group</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
*for participants from the 12.5 mg combination dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study.</description>
        </group>
        <group group_id="P6">
          <title>CCT/006 - 25 mg Dose Group* → 25 mg Combination Group</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
*for participants from the 25 mg combination dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study.</description>
        </group>
        <group group_id="P7">
          <title>Metformin Monotherapy Group* → 12.5 mg Combination Group</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
*for participants from the metformin 500 mg or 750 mg dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study.</description>
        </group>
        <group group_id="P8">
          <title>Metformin Monotherapy Group* → 25 mg Combination Group</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
*for participants from the metformin 500 mg or 750 mg dosing ARM of the SYR-322/CCT-006 (NCT01318109) core phase 2/3 metformin add-on study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled - Long-Term Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="91"/>
                <participants group_id="P6" count="90"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="91"/>
                <participants group_id="P6" count="90"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Complications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Entered - Long-Term Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97">Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P2" count="102">Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P3" count="46">Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P4" count="49">Patients participated in CCT-005 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P5" count="90">Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P6" count="87">Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P7" count="50">Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.</participants>
                <participants group_id="P8" count="49">Patients participated in CCT-006 but not entered OCT-005 are excluded in Participant Flow.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80">296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.</participants>
                <participants group_id="P2" count="89">296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.</participants>
                <participants group_id="P3" count="38">296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.</participants>
                <participants group_id="P4" count="42">296 participants enrolled and 294 completed glimepiride add-on study and entered the present study.</participants>
                <participants group_id="P5" count="81">280 participants enrolled and 276 completed metformin add-on study and entered the present study.</participants>
                <participants group_id="P6" count="83">280 participants enrolled and 276 completed metformin add-on study and entered the present study.</participants>
                <participants group_id="P7" count="49">280 participants enrolled and 276 completed metformin add-on study and entered the present study.</participants>
                <participants group_id="P8" count="46">280 participants enrolled and 276 completed metformin add-on study and entered the present study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of Excluded Medications</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="142"/>
            <count group_id="B4" value="145"/>
            <count group_id="B5" value="589"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Participants randomized in core phase 2/3 glimepiride add-on study, excluding those randomized to the “glimepiride monotherapy group” was 304. Participants randomized in core phase 2/3 metformin add-on study, excluding those randomized to the “metformin monotherapy group” was 287. The following are included in baseline: Column 1: 7 patients participated in CCT-005 but not entered OCT-005; Column 2: 1 participated in CCT-005 but not entered OCT-005; Column 3: 2 participated in CCT-006 but not entered OCT-005; Column 4: 9 participated in CCT-006 but not entered OCT-005.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93" spread="9.50"/>
                    <measurement group_id="B2" value="105" spread="8.92"/>
                    <measurement group_id="B3" value="142" spread="8.12"/>
                    <measurement group_id="B4" value="145" spread="8.41"/>
                    <measurement group_id="B5" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events.</title>
        <description>Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.</description>
        <time_frame>52 Weeks.</time_frame>
        <population>Full Analysis Set was defined as the population of participants randomized in the core phase 2/3 SYR-322/CCT-005 (NCT01318083) or SYR-322/CCT-006 (NCT01318109) add-on studies and received at least 1 dose of the investigational products (SYR-322DB in combination with glimepiride or metformin) for the treatment period were identified for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events.</title>
          <description>Treatment-emergent adverse events (TEAE) are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.</description>
          <population>Full Analysis Set was defined as the population of participants randomized in the core phase 2/3 SYR-322/CCT-005 (NCT01318083) or SYR-322/CCT-006 (NCT01318109) add-on studies and received at least 1 dose of the investigational products (SYR-322DB in combination with glimepiride or metformin) for the treatment period were identified for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Adverse Event (≥3% Frequency Threshold)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 8).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 8).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.506"/>
                    <measurement group_id="O2" value="-0.65" spread="0.515"/>
                    <measurement group_id="O3" value="-0.53" spread="0.486"/>
                    <measurement group_id="O4" value="-0.59" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 12).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 12).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.626"/>
                    <measurement group_id="O2" value="-0.72" spread="0.589"/>
                    <measurement group_id="O3" value="-0.61" spread="0.576"/>
                    <measurement group_id="O4" value="-0.71" spread="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 16).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 16.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 16).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.685"/>
                    <measurement group_id="O2" value="-0.76" spread="0.660"/>
                    <measurement group_id="O3" value="-0.69" spread="0.614"/>
                    <measurement group_id="O4" value="-0.78" spread="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 20).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 20.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 20).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.754"/>
                    <measurement group_id="O2" value="-0.70" spread="0.689"/>
                    <measurement group_id="O3" value="-0.67" spread="0.648"/>
                    <measurement group_id="O4" value="-0.78" spread="0.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 24).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 24.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 24).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.823"/>
                    <measurement group_id="O2" value="-0.70" spread="0.740"/>
                    <measurement group_id="O3" value="-0.68" spread="0.668"/>
                    <measurement group_id="O4" value="-0.78" spread="0.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 28).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 28.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 28).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.841"/>
                    <measurement group_id="O2" value="-0.76" spread="0.721"/>
                    <measurement group_id="O3" value="-0.70" spread="0.659"/>
                    <measurement group_id="O4" value="-0.84" spread="0.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 32).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 32.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 32).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.868"/>
                    <measurement group_id="O2" value="-0.77" spread="0.736"/>
                    <measurement group_id="O3" value="-0.67" spread="0.644"/>
                    <measurement group_id="O4" value="-0.81" spread="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 36).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 36.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 36).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.881"/>
                    <measurement group_id="O2" value="-0.77" spread="0.745"/>
                    <measurement group_id="O3" value="-0.67" spread="0.659"/>
                    <measurement group_id="O4" value="-0.79" spread="0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 40).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 40.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 40).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.799"/>
                    <measurement group_id="O2" value="-0.74" spread="0.779"/>
                    <measurement group_id="O3" value="-0.63" spread="0.676"/>
                    <measurement group_id="O4" value="-0.74" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 44).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 44.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 44).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.726"/>
                    <measurement group_id="O2" value="-0.71" spread="0.666"/>
                    <measurement group_id="O3" value="-0.47" spread="0.787"/>
                    <measurement group_id="O4" value="-0.70" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 48).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 48.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 48).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.706"/>
                    <measurement group_id="O2" value="-0.61" spread="0.660"/>
                    <measurement group_id="O3" value="-0.36" spread="0.762"/>
                    <measurement group_id="O4" value="-0.62" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Week 52).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Week 52.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Week 52).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.652"/>
                    <measurement group_id="O2" value="-0.53" spread="0.643"/>
                    <measurement group_id="O3" value="-0.29" spread="0.744"/>
                    <measurement group_id="O4" value="-0.53" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (Final Visit).</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline.</description>
        <time_frame>Baseline and Final Visit (up to 52).</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (Final Visit).</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit and glycosylated hemoglobin collected at baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>percentage of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.838"/>
                    <measurement group_id="O2" value="-0.58" spread="0.791"/>
                    <measurement group_id="O3" value="-0.44" spread="0.720"/>
                    <measurement group_id="O4" value="-0.58" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 8).</title>
        <description>The change between the value of fasting blood glucose collected at week 8 and baseline.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 8).</title>
          <description>The change between the value of fasting blood glucose collected at week 8 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="26.50"/>
                    <measurement group_id="O2" value="-19.6" spread="30.53"/>
                    <measurement group_id="O3" value="-22.0" spread="22.76"/>
                    <measurement group_id="O4" value="-23.4" spread="26.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 12).</title>
        <description>The change between the value of fasting blood glucose collected at week 12 and baseline.</description>
        <time_frame>Baseline and Week 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 12).</title>
          <description>The change between the value of fasting blood glucose collected at week 12 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" spread="32.19"/>
                    <measurement group_id="O2" value="-18.1" spread="29.05"/>
                    <measurement group_id="O3" value="-22.9" spread="24.04"/>
                    <measurement group_id="O4" value="-24.2" spread="27.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 16).</title>
        <description>The change between the value of fasting blood glucose collected at week 6 and baseline.</description>
        <time_frame>Baseline and Week 16.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 16).</title>
          <description>The change between the value of fasting blood glucose collected at week 6 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.3" spread="34.37"/>
                    <measurement group_id="O2" value="-17.8" spread="32.22"/>
                    <measurement group_id="O3" value="-21.8" spread="26.86"/>
                    <measurement group_id="O4" value="-26.1" spread="26.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 20).</title>
        <description>The change between the value of fasting blood glucose collected at week 20 and baseline.</description>
        <time_frame>Baseline and Week 20.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 20).</title>
          <description>The change between the value of fasting blood glucose collected at week 20 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="31.75"/>
                    <measurement group_id="O2" value="-22.3" spread="30.93"/>
                    <measurement group_id="O3" value="-23.4" spread="27.88"/>
                    <measurement group_id="O4" value="-26.1" spread="26.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 24).</title>
        <description>The change between the value of fasting blood glucose collected at week 24 and baseline.</description>
        <time_frame>Baseline and Week 24.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 24).</title>
          <description>The change between the value of fasting blood glucose collected at week 24 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="31.69"/>
                    <measurement group_id="O2" value="-25.0" spread="32.68"/>
                    <measurement group_id="O3" value="-25.6" spread="24.22"/>
                    <measurement group_id="O4" value="-26.3" spread="28.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 28).</title>
        <description>The change between the value of fasting blood glucose collected at week 28 and baseline.</description>
        <time_frame>Baseline and Week 28.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 28).</title>
          <description>The change between the value of fasting blood glucose collected at week 28 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" spread="36.87"/>
                    <measurement group_id="O2" value="-25.9" spread="33.67"/>
                    <measurement group_id="O3" value="-25.8" spread="26.16"/>
                    <measurement group_id="O4" value="-28.2" spread="29.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 32).</title>
        <description>The change between the value of fasting blood glucose collected at week 32 and baseline.</description>
        <time_frame>Baseline and Week 32.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 32).</title>
          <description>The change between the value of fasting blood glucose collected at week 32 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="37.47"/>
                    <measurement group_id="O2" value="-26.1" spread="30.69"/>
                    <measurement group_id="O3" value="-23.2" spread="25.71"/>
                    <measurement group_id="O4" value="-28.2" spread="29.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 36).</title>
        <description>The change between the value of fasting blood glucose collected at week 36 and baseline.</description>
        <time_frame>Baseline and Week 36.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 36).</title>
          <description>The change between the value of fasting blood glucose collected at week 36 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5" spread="34.16"/>
                    <measurement group_id="O2" value="-26.7" spread="33.12"/>
                    <measurement group_id="O3" value="-23.4" spread="24.00"/>
                    <measurement group_id="O4" value="-26.0" spread="31.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 40).</title>
        <description>The change between the value of fasting blood glucose collected at week 40 and baseline.</description>
        <time_frame>Baseline and Week 40.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 40).</title>
          <description>The change between the value of fasting blood glucose collected at week 40 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="33.44"/>
                    <measurement group_id="O2" value="-22.7" spread="30.19"/>
                    <measurement group_id="O3" value="-19.8" spread="24.81"/>
                    <measurement group_id="O4" value="-23.2" spread="31.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 44).</title>
        <description>The change between the value of fasting blood glucose collected at week 44 and baseline.</description>
        <time_frame>Baseline and Week 44.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 44).</title>
          <description>The change between the value of fasting blood glucose collected at week 44 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="31.69"/>
                    <measurement group_id="O2" value="-21.9" spread="29.33"/>
                    <measurement group_id="O3" value="-16.3" spread="26.22"/>
                    <measurement group_id="O4" value="-24.0" spread="31.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 48).</title>
        <description>The change between the value of fasting blood glucose collected at week 48 and baseline.</description>
        <time_frame>Baseline and Week 48.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 48).</title>
          <description>The change between the value of fasting blood glucose collected at week 48 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="28.29"/>
                    <measurement group_id="O2" value="-16.6" spread="30.68"/>
                    <measurement group_id="O3" value="-14.3" spread="24.22"/>
                    <measurement group_id="O4" value="-23.3" spread="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Week 52).</title>
        <description>The change between the value of fasting blood glucose collected at week 52 and baseline.</description>
        <time_frame>Baseline and Week 52.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Week 52).</title>
          <description>The change between the value of fasting blood glucose collected at week 52 and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="31.74"/>
                    <measurement group_id="O2" value="-11.9" spread="30.11"/>
                    <measurement group_id="O3" value="-14.0" spread="26.92"/>
                    <measurement group_id="O4" value="-16.1" spread="29.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (Final Visit).</title>
        <description>The change between the value of fasting blood glucose collected at final visit and baseline.</description>
        <time_frame>Baseline and Final Visit (up to Week 52).</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (Final Visit).</title>
          <description>The change between the value of fasting blood glucose collected at final visit and baseline.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="33.73"/>
                    <measurement group_id="O2" value="-13.0" spread="34.68"/>
                    <measurement group_id="O3" value="-16.4" spread="25.81"/>
                    <measurement group_id="O4" value="-17.7" spread="29.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).</title>
        <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
        <time_frame>Baseline and Week 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).</title>
          <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="43.24"/>
                    <measurement group_id="O2" value="80.1" spread="47.77"/>
                    <measurement group_id="O3" value="61.6" spread="38.72"/>
                    <measurement group_id="O4" value="64.0" spread="34.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).</title>
        <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
        <time_frame>Baseline and Week 24.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).</title>
          <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" spread="38.74"/>
                    <measurement group_id="O2" value="77.9" spread="42.68"/>
                    <measurement group_id="O3" value="60.7" spread="34.96"/>
                    <measurement group_id="O4" value="62.4" spread="32.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).</title>
        <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
        <time_frame>Baseline and Week 52.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).</title>
          <description>The change between the value of blood glucose measured by the meal tolerance test collected at week 52 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="46.24"/>
                    <measurement group_id="O2" value="83.2" spread="43.61"/>
                    <measurement group_id="O3" value="62.5" spread="42.91"/>
                    <measurement group_id="O4" value="62.7" spread="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).</title>
        <description>The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
        <time_frame>Baseline and Final Visit (up to Week 52).</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).</title>
          <description>The change between the value of blood glucose measured by the meal tolerance test collected at final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="45.47"/>
                    <measurement group_id="O2" value="84.9" spread="44.35"/>
                    <measurement group_id="O3" value="63.5" spread="43.06"/>
                    <measurement group_id="O4" value="63.7" spread="32.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug.</time_frame>
      <desc>The following are included in Adverse Events tables: Column 1: 7 patients participated in CCT-005 but not entered OCT-005; Column 2: 1 participated in CCT-005 but not entered OCT-005; Column 3: 2 participated in CCT-006 but not entered OCT-005; Column 4: 9 participated in CCT-006 but not entered OCT-005.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="113" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>General Manager</name_or_title>
      <organization>Japan Development Center, Pharmaceutical Development Division</organization>
      <phone>+81-6-6204-5257</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

